Schematic representation of the reduction in BCR-ABL transcript numbers after start of imatinib for CML in chronic phase. The scales show log reduction from a standardized baseline (left scale) and the ratio of BCR-ABL transcript numbers to a control gene expressed as a percentage (right scale). Reproduced with permission from Dr Timothy Hughes (Adelaide).